Certain Maternal Antibodies in Relation to Doppler in Hypertension With Pregnancy

Role of Maternal Anticardiolipin and Anti-B2 Glycoprotein I Antibodies in Correlation With Fetal Doppler in Prediction of Adverse Pregnancy Outcome in Patients With Preeclampsia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03214393

Enrollment

100

Registered

2017-07-11

Start date

2017-08-01

Completion date

2018-08-30

Last updated

2017-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-Eclampsia

Brief summary

Relation of certain maternal serum antibodies to Doppler changes will be studied in cases suffering from hypertension with pregnancy.

Detailed description

Assessment will be done for maternal serum anti-beta 2 glycoprotein 1 antibodies and anticardiolipin antibodies in cases of preeclampsia after 32 weeks of pregnancy. In addition, fetal Doppler changes will be assessed.

Interventions

DIAGNOSTIC_TESTDoppler

Doppler will be done to pregnant women with Pre-Eclampsia

DIAGNOSTIC_TESTserum antibodies

serum antibodies will be measured for pregnant women with Pre-Eclampsia

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Pregnant women 32 weeks or more gestational age * Pre-eclampsia * Singleton pregnancy

Exclusion criteria

* Intrauterine fetal death * Fetus with apparent congenital anomalies * Pregnant females with other medical disorders * History of essential hypertension. * History of antepartum hemorrhage. * History of rupture of membranes.

Design outcomes

Primary

Measure	Time frame	Description
percentage of cases that develop severe pre-eclampsia	It will be calculated after 1 year from the start of the study	percentage of cases that develop severe pre-eclampsia will be assessed by an investigator

Countries

Egypt

Contacts

Primary ContactDoaa Sh Belal, MD

doaash@live.com0020223682030

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026